Chinese University of Hong Kong Institute of Chinese Medicine; Chinese University of Hong Kong; and BUPA Foundation
The Chinese University of Hong Kong
Kwong Wah Hospital
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong
Tel or Tel  26323593
email or Email firstname.lastname@example.org
Department of Medicine and Therapeutics, The Chinese University of Hong Kong
School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong
Tel or Tel  26323146
email or Email email@example.com
School of Pharmacy, The Chinese University of Hong Kong
A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease
Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease
Curcumin for AD
Nervous System Diseases
Curcumin and ginkgo extract
Inclusion: Possible or probable AD.
Exclusion: Anticoagulant or antiplatelet treatment or bleeding risk factors; currently smoking; or other severe illness.
Both Male and Female
Setting up formulation, patient recruitment, and assay procedures at 0, 1, and 6 months, in preparation for a later clinical trial testing the effectiveness of curcumin and ginkgo in slowing AD progression.
Change in biochemical measures of AD: Plasma isoprostane and A-beta levels at 1 and 6 months. Change in cognitive measures of AD: MMSE at 6 months. Change in others: cholesterol, lipid, C reactive protein, and metal levels in serum at 1 and 6 months. Curcumin and metabolites at 1 month.
|No documents yet.|